PDF (2.8 MB)
Collect
Submit Manuscript
Show Outline
Figures (2)

Communication | Open Access

Designing a Novel Nano-Vaccine against SARS-CoV-2

Ang Gao1,2,#Hui Liang2,#Qi Shen2Cheng Zhou2Xiao Min Chen2Jing Tian2Xueling Li2Zexi Liu2Jian Ni1()Daxiang Cui1,2()
Institute of Nano Biomedicine and Engineering, Shanghai Engineering Research Centre for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, 800 Dong Chuan RD, Shanghai 200240, PR China
National Engineering Research Center for Nanotechnology, 28 East Jiang Chuan Road, Shanghai 200241, China

# These authors contributed equally to this work.

Show Author Information

Abstract

The new coronavirus SARS-CoV-2 has become a global pandemic, which has had a huge impact on the lives of people around the world and has caused huge impacts and losses on global economic development. To now, there is still no effective drug or therapy against coronavirus. A large number of studies have shown that vaccines are the ultimate weapon to eliminate major infectious diseases. The development of new vaccines against new coronaviruses is the best way to prevent new coronavirus infections. In this study, we developed a new vaccine against the new coronavirus by combining our self-developed nano adjuvant loaded with carnosine graphene oxide adjuvant with loaded with CpG molecule and RBD protein antigen. Our results showed that this vaccine can produce high titer anti-SARS-CoV-2 RBD antibody neutralizing SARS-CoV-2 in mice within 2 weeks.

References

[1]

M. Mahévas, V.T. Tran, M. Roumier, et al., Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. Bmj, 2020, 369: m1844.

[2]

C.D. Spinner, R.L. Gottlieb, G.J. Criner, et al., Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. Jama, 2020.

[3]

P. Horby, W.S. Lim, J.R. Emberson, et al., Dexamethasone in hospitalized patients with Covid-19-preliminary report. N Engl J Med, 2020.

[4]

H. Wang, Y. Zhang, B. Huang, et al., Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell, 2020, 182: 713-721. e9.

[5]

T.R.F. Smith, A. Patel, S. Ramos, et al., Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun, 2020, 11: 2601.

[6]

D. Yin, S. Ling, X. Tian, et al., A single dose SARS-CoV-2 simulating particle vaccine induces potent neutralizing activities. BioRxiv, 2020: 093054.

[7]

F.C. Zhu, Y.H. Li, X.H. Guan, et al., Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet, 2020, 395: 1845-1854.

[8]

N. van Doremalen, T. Lambe, A. Spencer, et al., ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 2020.

[9]

P.J. Hotez, M.E. Bottazzi, Developing a low-cost and accessible COVID-19 vaccine for global health. PLoS Negl Trop Dis, 2020, 14: e0008548.

[10]

L. Dai, T. Zheng, K. Xu, et al., A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell, 2020, 182: 722-733.

[11]

M.A. Anwar, M. Shah, J. Kim, et al., Recent clinical trends in Toll-like receptor targeting therapeutics. Med Res Rev, 2019, 39: 1053-1090.

[12]

M. Liu, R.S. O'Connor, S. Trefely, et al., Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal. Nat Immunol, 2019, 20: 265-275.

[13]

C. Meng, X. Zhi, C. Li, et al., Graphene oxides decorated with carnosine as an adjuvant to modulate innate immune and improve adaptive immunity in vivo. ACS Nano, 2016, 10: 2203-2213.

Nano Biomedicine and Engineering
Pages 321-324
Cite this article:
Gao A, Liang H, Shen Q, et al. Designing a Novel Nano-Vaccine against SARS-CoV-2. Nano Biomedicine and Engineering, 2020, 12(4): 321-324. https://doi.org/10.5101/nbe.v12i4.p321-324
Metrics & Citations  
Article History
Copyright
Rights and Permissions
Return